FDA Stalls On Collegium's 'Abuse-Deterrent' Painkiller
The U.S. Food and Drug Administration didn't finish its review — which had been expected on Monday — of Collegium Pharmaceutical Inc.'s purported abuse-deterrent opioid painkiller that an FDA panel supported...To view the full article, register now.
Already a subscriber? Click here to view full article